I am happy to share that @NatureComms has published our latest research from the @DKFZ. DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts. Here’s the link to the article:.👇. 1/7.

RT @DKFZ: Ashish Goyal, Jens Bauer und Joschka Hey erhalten den diesjährigen #WaltraudLewenzPreis für ihre Arbeit über die Identifizierung….

Join millions who have switched to Grok.

RT @anand_mt: Trackplot: a fast and minimal dependency R script for epigenomic enrichment plots . . .

Congratulations to all authors involved in this beautiful study about Juvenile Myelomonocytic Leukemia! .I am pleased to have contributed to this work that not only demonstrates the oncofetal reprogramming of this childhood cancer, but also identifies therapeutic vulnerabilities.

RT @DKFZ: Epigenetisch wirkende Medikamente ermöglichen, dass Bereiche des Erbguts abgelesen werden, die vorher blockiert waren. Das führt….

Our main focus @Cytoreason is to utilize computational disease models to gain a better understanding of disease mechanisms, prioritize indications, and identify novel targets for various diseases. 7/7.

Although my time as a Postdoctoral Researcher at DKFZ has come to an end, I feel fortunate to have the opportunity to continue working in the same field as a Senior Bioinformatics Scientist at @Cytoreason. 6/7.

This work is the product of a great collaboration with .Jens Bauer and @JulianeWalz from the @uni_tue and would not have been possible without the continuous efforts of Ashish Goyal, Christoph Plass, and many others from the Cancer Epigenomics division @DKFZ. 5/7.

We confirmed the presence of TINPATs in a broad range of cancer types, particularly in AML patients after in vivo treatment with the DNMT inhibitor Decitabine, and highlighted their potential when combined with immunotherapy. 4/7.

These transcripts play a crucial role in generating treatment-induced neopeptides (t-neopeptides) that are presented on the human leukocyte antigen (HLA), subsequently inducing a T-cell response that effectively targets and destroys cancer cells. 3/7.

Our study found that epigenetic drug treatment, such as the inhibition of DNMT and HDAC, can lead to the derepression of ERV-derived, treatment-induced novel polyadenylated transcripts (TINPATs). 2/7.

RT @WeizmannScience: One in 400 people among the general population – and 1 in 40 Ashkenazi Jews – is born with mutations in the BRCA genes….

RT @mllprada: Very happy that this is out! Thanks to the work of many passionate scientists from Academia, Industry and Clinics, to the gen….

RT @NAC_Regensburg: We completed the first whole genome #DNAmethylation profiles in #copd, revealing potential disease regulators 👇. High‐….

RT @Simgekelekci: Delighted to share our story about enhancer hijacking event! .First contributing article of my PhD @DKFZ . Many more to….

RT @IntJCanc: 🔥📢Read the new study led by our very own Editor-in-Chief C. Plass @DKFZ and R. Scherz-Shourval @WeizmannScience on the epigen….

RT @HeyJosch: Have you ever asked yourself how myeloid cells are reprogrammed to become tumor-associated macrophages (TAMs)?. Our recent pu….

If you haven’t seen our previous work on epigenetic reprogramming of the TME, check out our Cancer Research article on CAFs. 6/n.

Thanks to all friends and collaborators who made this project possible! Congratulations @CoralHalperin, @mp_hartmann, @MayerShimrit, @MaxSchoenung, @dblipka1, @shouval, and Christoph Plass. 5/n.

Similarly, immunosuppressive TAM functions were identified, such as induction of the immune inhibitory receptor-ligand PD-L1 by Promoter hypomethylation of Cd274. 5/n.